# E-DRUG: Re: NSAIDS - do they differ? **URL:** \ **Category:** e-drug\ **Created:** [June 1, 1997, 1:13pm UTC](https://talk.edrugplus.org/t/e-drug-re-nsaids-do-they-differ/905 "1997-06-01T13:13:34Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![myhr](https://avatars.discourse-cdn.com/v4/letter/m/f07891/32.png) [@myhr](https://talk.edrugplus.org/u/myhr)\ **Post date:** [June 1, 1997, 1:13pm UTC](https://talk.edrugplus.org/t/e-drug-re-nsaids-do-they-differ/905/1 "1997-06-01T13:13:34Z")
E-drug: NSAIDS - do they differ? ------------------------------ Dear Rodolfo; In the last issue of International Pharmaceutical Journal is a one page summary of the review done by the MeRec centre in the UK of meloxicam and aceclofenac. I think you should ask for the full text by fax to: MeReC Bulletin National Prescribing Centre The Infirmary 70 Pembroke Place Liverpool L69 3GF England Fax: +44 151 794 8144 The conclusion is that there are no data to suggest that any one NSAID is more effective than the others. The evidence regarding meloxicam and aceclofenac suggests that they too are of a similar efficacy to the other NSAIDs. No published data are available comparing less toxic NSAIDs, such as ibuprofen, with meloxicam or aceclofenac. Until published evidence shows an advantage for these products, ibuprofen remains the agent of choice when an NSAID is required. > From a note in Scrip no 2234 I understand that the debate is lively and heated and several companies make poorly documented claims about differences in GI-effects. Regards Kirsten Ms Kirsten Myhr, MScPharm, MPH Bygdoy Alle 58B 0265 Oslo Norway Tel: +47 22 56 05 85 (h) Fax: +47 22 24 90 17 (w) Tel: +47 22 24 90 04 (w) E-mail: myhr@online.no or (w): kirsten.myhr@helsetilsynet.dep.telemax.no -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.